Feng Jun, Yasen Aimaiti, Dai Tianxing, Liang Runbin, Liao Zhihong, He Ping, Lin Zhihong, Wang Guoying
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Liver Res. 2023 Jun 9;7(2):156-160. doi: 10.1016/j.livres.2023.06.002. eCollection 2023 Jun.
Adenosquamous carcinoma (ASC) is a rare histological type of intrahepatic cholangiocarcinoma, which includes both adenocarcinoma and squamous cell carcinoma. The clinical features, physical examination, routine laboratory tests, and imaging examinations of patients with ASC are nonspecific. ASC is easily misdiagnosed as hepatocellular carcinoma, and patients with ASC always have a poor prognosis. This study reports a patient with ASC who was diagnosed based on pathological results, underwent surgical resection, and received postoperative chemotherapy (gemcitabine plus cisplatin) combined with immunotherapy (sintilimab). During the 1-year follow-up, the patient was in good condition, and no signs of cancer recurrence were noted. This case highlights that surgical resection and chemotherapy combined with immunotherapy may be feasible for patients with ASC.
腺鳞癌（ASC）是肝内胆管癌一种罕见的组织学类型，它同时包含腺癌和鳞状细胞癌成分。ASC患者的临床特征、体格检查、常规实验室检查及影像学检查均无特异性。ASC很容易被误诊为肝细胞癌，且ASC患者的预后通常较差。本研究报告了1例基于病理结果确诊的ASC患者，该患者接受了手术切除，并接受了术后化疗（吉西他滨联合顺铂）及免疫治疗（信迪利单抗）。在1年的随访期间，患者状况良好，未发现癌症复发迹象。该病例表明，手术切除及化疗联合免疫治疗对ASC患者可能是可行的。
